BioExec has consistently provided a glowing endorsement of Dr Richard Hopkins - "Richard is good...... Richard has set things straight....," from post February 8, 2016.
ds observed that during the last 6 months, Richard had 'virtually vanished' but any decision to leave was most likely mutual, from post September 14, 2016.
So, what was happening behind the scenes. The biotech world must be extremely small particularly with meeting up with old friends and scientific peers at any number of international conferences. One of the challenges faced by the CEO would have been moving the POC data pack forward. BioExec touched upon it in his post of January 28, 2016;
"PYC needs to get to at least a reasonable PK data package sometime in 2016 via IV dosing" and "they need to take the next step in the development process, and show that this compound IV dosed has therapeutically relevant PK profile."
It would be unsurprising that the CEO was working tirelessly behind the scenes in setting up the transition of leadership to take Phylogica forward to the next stage of development.
PYC Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)